Vol. 20/No. 24 | OncologyLive

The Dividing Line for Germline Mutation Testing Is Often Arbitrary

December 18, 2019

Although hereditary cancer risk was defined solely by family history in the not-so-distant past, today increasingly robust data may help define an individual’s heightened lifetime risk based on the presence of specific molecular findings within the germline

Novel Targeted Therapies Show Promise in Cholangiocarcinoma

December 17, 2019

During a recent OncLive Peer Exchange® roundtable, experts discussed novel targeted agents for cholangiocarcinomas progressing through the pipeline, such as infigratinib and pemigatinib, which are selective pan-inhibitors of FGFR fusions/translocations being evaluated in phase III trials.

PARP Inhibitors Gain a Foothold in Prostate Cancer

December 12, 2019

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.

Investigators Test Tumor-Treating Fields in Lung Cancer

December 11, 2019

Investigators are attempting to advance the late-stage non–small cell lung cancer treatment paradigm by combining an emerging antimitotic modality with standard-of-care therapies in the phase III LUNAR trial.